Cytokinetics (CYTK)
Developer of muscle-directed medicines led by MYQORZO for hypertrophic cardiomyopathy.
Something off on this page? Send us feedback.
Develops and commercializes muscle-directed medicines, led by MYQORZO for obstructive hypertrophic cardiomyopathy, while advancing cardiac myosin drugs for other forms of hypertrophic cardiomyopathy and heart failure. Revenue now comes chiefly from its first commercial product, with additional programs dependent on clinical and regulatory outcomes.
Develops and commercializes small-molecule medicines that alter muscle contractility, centered on a specialty cardiology franchise. MYQORZO (aficamten), an oral cardiac myosin inhibitor for adults with symptomatic obstructive hypertrophic cardiomyopathy, is launched in the United States and Germany; wider international access combines direct launches with regional partners. Pairs in-house muscle-biology research with a targeted sales model focused on specialist cardiologists and treatment centers.
Extends aficamten into non-obstructive and pediatric hypertrophic cardiomyopathy while advancing omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for a hypercontractile form of preserved-ejection-fraction heart failure. CK-089 keeps an early neuromuscular program in the portfolio. Product revenue currently depends on MYQORZO adoption, reimbursement, and required safety monitoring, while further growth depends on regulatory review and clinical-trial outcomes.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 1, 2026 | Morgan Stanley | Upgrade | ||
| Aug 13, 2026 | Barclays | Reiterate | Rating: —Target: $87 | Target: $110 |
| Aug 10, 2026 | Truist Financial | Target | Target: $106 | Target: $112 |
| Aug 7, 2026 | Needham | Reiterate | Rating: —Target: $84 | Target: $112 |
| Aug 7, 2026 | RBC Capital | Reiterate | Rating: —Target: $117 | Target: $112 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.17B · Total debt $1.27B · Total assets $1.92B · Shareholders' equity −$173.5M
- Revenue
- $31.9M
- Operating income
- −$175.9M
- Net income
- −$198.8M
No dividends on record.
| Institutions | ≈ 127.53% | 158.70M shares | |
|---|---|---|---|
| 512 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.76% | 942.2K shares | |
| 16 holders · as of Sep 15, 2026 | |||
| Adds to | 128.29% | ||
124.43M company shares as of Aug 28, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (139.02M in the company's Sep 22, 2026 report, 124.43M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 128.29%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 16.15% | 20.09M | as of Jun 30, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 15.04% | 18.72M | as of Jun 30, 2026 |
Wellington Management Group LLPInstitution | 5.57% | 6.93M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.39% | 6.71M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.22% | 6.49M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 15, 2026 | Robert I. Blum | director, officer: President & CEO | −97,926 | $69.33 |
| Sep 14, 2026 | Robert I. Blum | director, officer: President & CEO | −7,500 | $73.44 |
| Sep 15, 2026 | Robert E. Landry | director | −1,000 | $72.13 |
| Sep 11, 2026 | Robert E. Landry | director | −1,000 | $74.66 |
| Sep 8, 2026 | Fady Ibraham Malik | officer: EVP Research & Development | −3,500 | $75.46 |
- Bristol-Myers Squibb
Only approved cardiac myosin inhibitor in oHCM; Camzyos at $1.1B 2025 revenue.
- Edgewise Therapeutics
Cardiac sarcomere modulator EDG-7500 in Phase 2 for both oHCM and nHCM.
- Novartis (ADR)
Entresto (sacubitril/valsartan), the dominant ARNI standard of care in HFrEF.
- AstraZeneca (ADR)
Farxiga (dapagliflozin), SGLT2 inhibitor approved for HFrEF and HFpEF.
- Eli Lilly
Jardiance (empagliflozin), SGLT2 leader approved for HFrEF and HFpEF.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cytokinetics | $67.82 | +0.38% | $8.41B | — | — | 118.5 | −57.1% |
| Bristol-Myers Squibb | $62.36 | −0.42% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Edgewise Therapeutics | $44.77 | +0.28% | $4.80B | — | — | — | — |
| Novartis (ADR) | $141.58 | +0.43% | $267.96B | 21.3 | 15.1 | 4.8 | +0.9% |
| AstraZeneca (ADR) | $168.67 | +0.34% | $260.70B | 25.2 | 15.9 | 4.2 | +6.4% |
| Eli Lilly | $1,171.95 | +0.61% | $1.10T | 39.1 | 28.7 | 13.8 | +47.7% |
| Median | 23.3 | 15.5 | 4.5 | +6.1% |